Last reviewed · How we verify
GSP 301 NS — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
GSP 301 NS (GSP 301 NS) — Glenmark Specialty S.A.. GSP 301 NS is a nasal spray formulation designed to deliver its active pharmaceutical ingredient through the nasal mucosa for systemic or local therapeutic effect.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSP 301 NS TARGET | GSP 301 NS | Glenmark Specialty S.A. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSP 301 NS CI watch — RSS
- GSP 301 NS CI watch — Atom
- GSP 301 NS CI watch — JSON
- GSP 301 NS alone — RSS
Cite this brief
Drug Landscape (2026). GSP 301 NS — Competitive Intelligence Brief. https://druglandscape.com/ci/gsp-301-ns. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing